Armis Identifies the Riskiest Assets Introducing Threats to Global Businesses
5.9.2023 16:00:00 EEST | Business Wire | Press release
Armis, the leading asset visibility and security company, today released new research identifying the riskiest connected assets posing threats to global businesses. Findings highlight risk being introduced to organizations through a variety of connected assets across device classes, emphasizing a need for a comprehensive security strategy to protect an organization’s entire attack surface in real-time.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230905844605/en/
Source: Data from the Armis Asset Intelligence Engine collected between August 2022 and July 2023.
“Continuing to educate global businesses about the evolving and increased risk being introduced to their attack surface through managed and unmanaged assets is a key mission of ours,” said Nadir Izrael, CTO and Co-Founder of Armis. “This intelligence is crucial to helping organizations defend against malicious cyberattacks. Without it, business, security and IT leaders are in the dark, vulnerable to blind spots that bad actors will seek to exploit.”
Armis’ research, analyzed from the Armis Asset Intelligence Engine, focuses on connected assets with the most attack attempts, weaponized Common Vulnerabilities and Exposures (CVEs) and high-risk ratings to determine the riskiest assets.
Assets With The Highest Number of Attack Attempts
Armis found the top 10 asset types with the highest number of attack attempts were distributed across asset types: IT, OT, IoT, IoMT, Internet of Personal Things (IoPT) and Building Management Systems (BMS). This demonstrates that attackers care more about their potential access to assets rather than the type, reinforcing the need for security teams to account for all physical and virtual assets as part of their security strategy.
Top 10 device types with the highest number of attack attempts:
- Engineering workstations (OT)
- Imaging workstations (IoMT)
- Media players (IoT)
- Personal computers (IT)
- Virtual machines (IT)
- Uninterruptible power supply (UPS) devices (BMS)
- Servers (IT)
- Media writers (IoMT)
- Tablets (IoPT)
- Mobile phones (IoPT)
“Malicious actors are intentionally targeting these assets because they are externally accessible, have an expansive and intricate attack surface and known weaponized CVEs,” said Tom Gol, CTO of Research at Armis. “The potential impact of breaching these assets on businesses and their customers is also a critical factor when it comes to why these have the highest number of attack attempts. Engineering workstations can be connected to all controllers in a factory, imaging workstations will collect private patient data from hospitals and UPSs can serve as an access point to critical infrastructure entities, making all of these attractive targets for malicious actors with varying agendas, like deploying ransomware or causing destruction to society in the case of nation-state attacks. IT leaders need to prioritize asset intelligence cybersecurity and apply patches to mitigate this risk.”
Assets With Unpatched, Weaponized CVEs Vulnerable to Exploitation
Researchers identified a significant number of network-connected assets susceptible to unpatched, weaponized CVEs published before 1/1/2022. Zooming in on the highest percentage of devices of each type that had these CVEs between August 2022 and July 2023, Armis identified the list reflected in Figure A. Unpatched, these assets introduce significant risk to businesses.
Assets with a High-Risk Rating
Armis also examined asset types with the most common high-risk factors:
- Many physical devices on the list that take a long time to replace, such as servers and Programmable Logic Controllers (PLCs), run end-of-life (EOL) or end-of-support (EOS) operating systems. EOL assets are nearing the end of functional life but are still in use, while EOS assets are no longer actively supported or patched for vulnerabilities and security issues by the manufacturer.
- Some assets, including personal computers, demonstrated SMBv1 usage. SMBv1 is a legacy, unencrypted and complicated protocol with vulnerabilities that have been targeted in the infamous Wannacry and NotPetya attacks. Security experts have advised organizations to stop using it completely. Armis found that 74% of organizations today still have at least one asset in their network vulnerable to EternalBlue – an SMBv1 vulnerability.
- Many assets identified in the list exhibited high vulnerability scores, have had threats detected, have been flagged for unencrypted traffic or still have the CDPwn vulnerabilities impacting network infrastructure and VoIPs.
- Half (50%) of pneumatic tube systems were found to have an unsafe software update mechanism.
Additional research from Armis is available on the riskiest OT and ICS devices across critical infrastructure industries as well as the riskiest medical and IoT devices in clinical environments.
Learn more about Armis at www.armis.com.
About Armis
Armis, the leading asset visibility and security company, provides the industry’s first unified asset intelligence platform designed to address the new extended attack surface that connected assets create. Fortune 100 companies trust our real-time and continuous protection to see with full context all managed, unmanaged assets across IT, cloud, IoT devices, medical devices (IoMT), operational technology (OT), industrial control systems (ICS), and 5G. Armis provides passive cyber asset management, risk management, and automated enforcement. Armis is a privately held company and headquartered in California.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230905844605/en/
Contact information
Rebecca Cradick
Senior Director, Global Communications
Armis
pr@armis.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 14:42:00 EEST | Press release
2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (Photo: AETOSWire) Net profit from the Group’s businesses increased by 2,301% year-on-year (YoY), driven by the consolidation of Tendam and the mega-merger to form 2PointZero Group, and growth was also supported by new investments in African financial services, entry into the European packaging markets, and steady operational progress across all verticals, bringing the total reported net profit to AED 7.7 billion. Through continued operational integr
Datroway ® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 09:30:00 EEST | Press release
Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on results from the TROPION-Breast02phase 3 trial, which were presented at the 2025 European Society for Medical Oncology Congress and subsequently published in Annals of Oncology. In TROPION-Breast02, which included patients with metastatic TNBC who experienced early relapse following prior treatment, Datroway demonstrated a statis
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 09:30:00 EEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
Half-Year Report on SES’s Liquidity Contract31.7.2026 08:30:00 EEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES: Disclosure of Share Buyback Transactions31.7.2026 08:30:00 EEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
